Literature DB >> 17653101

The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.

Lingxia Chen1, Fuxiang Zhu, Juan Li, Hui Lu, Haiyan Jiang, Rita Sarkar, Valder R Arruda, Jinhui Wang, Jennifer Zhao, Glenn F Pierce, Qiulan Ding, Xuefeng Wang, Hongli Wang, Steven W Pipe, Xiang-Qin Liu, Xiao Xiao, Rodney M Camire, Weidong Xiao.   

Abstract

Coagulation factor VIII (FVIII) is secreted as a heterodimer consisting of a heavy chain (HC) and a light chain (LC), which can be expressed independently and reassociate with recovery of biological activity. Because of the size limitation of adeno-associated virus (AAV) vectors, a strategy for delivering the HC and LC separately has been developed. However, the FVIII HC is secreted 10-100-fold less efficiently than the LC. In this study, we demonstrated that the F309S mutation and enhanced B-domain glycosylations alone are not sufficient to improve FVIII HC secretion, which suggested a role of the FVIII LC in regulating HC secretion. To characterize this role of the FVIII LC, we compared FVIII HC secretion with and without the LC via post-translational protein trans-splicing. As demonstrated in vitro, ligation of the LC to the HC significantly increased HC secretion. Such HC secretion increases were also confirmed in vivo by hydrodynamic injection of FVIII intein plasmids into hemophilia A mice. Moreover, similar enhancement of HC secretion can also be observed when the LC is supplied in trans, which is probably due to the spontaneous association of the HC and the LC in the secretion pathway. In sum, enhancing the secretion of the FVIII HC polypeptide may require the proper association of the FVIII LC polypeptide in cis or in trans. These results may be helpful in designing new strategies to improve FVIII gene delivery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653101      PMCID: PMC2596977          DOI: 10.1038/sj.mt.6300268

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  35 in total

Review 1.  Biochemistry and physiology of blood coagulation.

Authors:  K G Mann
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  The ins and outs of gene expression control.

Authors:  Francine B Perler
Journal:  Nat Biotechnol       Date:  2004-07       Impact factor: 54.908

3.  Genetic engineering of factor VIII.

Authors:  R J Kaufman
Journal:  Nature       Date:  1989-11-09       Impact factor: 49.962

4.  A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

Authors:  J J Toole; D D Pittman; E C Orr; P Murtha; L C Wasley; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

5.  Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells.

Authors:  A J Dorner; L C Wasley; R J Kaufman
Journal:  J Biol Chem       Date:  1989-12-05       Impact factor: 5.157

6.  Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.

Authors:  Rita Sarkar; Renee Tetreault; Guangping Gao; Lili Wang; Peter Bell; Randy Chandler; James M Wilson; Haig H Kazazian
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

Review 7.  Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.

Authors:  Linda B Couto
Journal:  Semin Thromb Hemost       Date:  2004-04       Impact factor: 4.180

8.  Clinical gene transfer studies for hemophilia B.

Authors:  Katherine A High
Journal:  Semin Thromb Hemost       Date:  2004-04       Impact factor: 4.180

Review 9.  Coagulation factors with improved properties for hemophilia gene therapy.

Authors:  Steven W Pipe
Journal:  Semin Thromb Hemost       Date:  2004-04       Impact factor: 4.180

10.  Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells.

Authors:  D D Pittman; K N Tomkinson; R J Kaufman
Journal:  J Biol Chem       Date:  1994-06-24       Impact factor: 5.157

View more
  19 in total

1.  Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy.

Authors:  Juan Li; Wunchang Sun; Bing Wang; Xiao Xiao; Xiang-Qin Liu
Journal:  Hum Gene Ther       Date:  2008-09       Impact factor: 5.695

2.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

3.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

4.  Advances in Gene Delivery Systems.

Authors:  Kenya Kamimura; Takeshi Suda; Guisheng Zhang; Dexi Liu
Journal:  Pharmaceut Med       Date:  2011-10-01

5.  Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.

Authors:  Paul E Monahan; Clinton D Lothrop; Junjiang Sun; Matthew L Hirsch; Tal Kafri; Boris Kantor; Rita Sarkar; D Michael Tillson; Joseph R Elia; R Jude Samulski
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

Review 6.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

7.  Characterization of genome integrity for oversized recombinant AAV vector.

Authors:  Biao Dong; Hiroyuki Nakai; Weidong Xiao
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

8.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

Authors:  Jenny McIntosh; Peter J Lenting; Cecilia Rosales; Doyoung Lee; Samira Rabbanian; Deepak Raj; Nishil Patel; Edward G D Tuddenham; Olivier D Christophe; John H McVey; Simon Waddington; Arthur W Nienhuis; John T Gray; Paolo Fagone; Federico Mingozzi; Shang-Zhen Zhou; Katherine A High; Maria Cancio; Catherine Y C Ng; Junfang Zhou; Christopher L Morton; Andrew M Davidoff; Amit C Nathwani
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

9.  Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.

Authors:  Hui Lu; Lingxia Chen; Jinhui Wang; Bernd Huack; Rita Sarkar; Shangzhen Zhou; Ray Xu; Qiulan Ding; Xuefeng Wang; Hongli Wang; Weidong Xiao
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

10.  Enhanced factor VIII heavy chain for gene therapy of hemophilia A.

Authors:  Lingxia Chen; Hui Lu; Jinhui Wang; Rita Sarkar; Xiao Yang; Hongli Wang; Katherine A High; Weidong Xiao
Journal:  Mol Ther       Date:  2009-01-06       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.